There has been a recent increase in the frequency with which glucose-nonfermentative gram-negative rods cause infections in compromised patients. The treatment of this type of infection poses certain problems because the resistance of these organisms to commercially available beta-lactam and aminoglycoside antibiotics is generally greater than that of species of fermentative gram-negative rods and grampositive cocci. Furthermore, two species belonging to a same genus, such as Pseudomonas aeruginosa and Pseudomonas cepacia, are known to react in opposite ways to aminoglucoside antibiotics (3, 4) . Ceftizoxime was reported by Kamimura et al. (2) and Fu and Neu (1) to have a broad antibacterial spectrum and high antibacterial potency against various species of pathogens. Among the organisms used in these two works, P. aeruginosa was the sole species of nonfermentative gram-negative rods, with the exception of P. cepacia ATCC 25416, the type strain for the species, which was used by Kamimura et al. (2) . In this study, we compared the in vitro antibacterial activity of ceftizoxime against nonfermentative gram-negative rods with that of nine other antimicrobial agents.
The test antibiotics used in this study were ceftizoxime (Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan), carbenicillin, ticarcillin, piperacillin, kanamycin, dibekacin, gentamicin, nalidixic acid, tetracycline, and minocycline. A total of 215 clinical isolates comprising 10 named species of nonfermentative gram-negative rods from eight hospitals in Japan were used as test organisms. The source of isolation of the 215 strains is summarized in Table 1 .
The antibiotic susceptibility test was performed by the following methods. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method, using heart infusion agar (Difco Laboratories). The organism was grown in heart infusion broth (Difco Laboratories) at 30°C for 20 h, and 100-fold dilutions of the broth cultures were spot-inocu- 3.2->100 1.6-12.5 0.8-3.2 3.2->100 0.8->100 =0.2-12.5 0.8-100 50->100 50->100 3.2->100 50->100 >100 6.3->100 12.5-100 12.5-100 <0.2-0.8 6.3->100 12.5->100 100->100 3.2->100 >100 >100 25->100 25-100 12.5->100 =0.2-0.8 1.6-50 Against Pseudomonas putida, the three aminoglycosides were the most active of all of the antibiotics tested. The MICs of ceftizoxime for P. putida ranged from 0.8 to >100 ,ug/ml, but 50% of the test strains were inhibited by 25 ,tg of this drug per ml. The activity of ceftizoxime against 27 strains of P. cepacia was the most potent of the drugs tested, followed in descending order by piperacillin and minocycline, and the 90% inhibitory concentrations of these three drugs were 1.6, 6.3, and 6.3 jig/ml, respectively. Against Pseudomonas maltophilia, minocycline was the most active of all the antibiotics, and ceftizoxime and penicillin derivatives had no antibacterial potency.
Most strains of Achromobacter xylosoxidans were highly resistant to ceftizoxime. The concentration required to inhibit 90% of the strains of Alcaligenes faecalis was 12.5 ,ug/ml for ceftizoxime, 6.3,ug/ml for ticarcillin, and 1.6 ,ug/ml for piperacillin. In contrast, minocycline was the most active against Flavobacterium species and Acinetobacter calcoaceticus, but at 6.3 ,tg/ml, ceftizoxime inhibited the growth of 50% of the strains of Flavobacterium meningosepticum and A. calcoaceticus.
These results show that ceftizoxime was potent against P. cepacia, F. meningosepticum, A.
faecalis, and A. calcoaceticus and fairly active against P. aeruginosa and P. putida. Because of its potent antibacterial activity and low human toxicity, ceftizoxime is expected to be therapeutically effective against infection due to nonfermentative gram-negative rods.
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